Multiple specificities in the repertoire of a melanoma patient's cytolytic T-lymphocytes directed against tumor-antigen MAGE-1.A1
(1995) The Journal of Experimental Medicine — Vol. 182, n° 4, p. 1019-1028 (1995)
Files
1019.pdf
Open Access - Adobe PDF
- 880.4 KB
Details
- Authors
- Abstract
- Peptide MAGE-1.A1 is a nonamer derived from protein MAGE-1 that can associate with the HLA-A1 molecule. It was shown previously to be recognized by an antitumor cytolytic T lymphocyte (CTL) clone derived from the blood of melanoma patient MZ2. We derived two other anti-MAGE-1.A1 CTL clones from different blood samples of the same patient and compared the fine specificity of recognition of the three CTL by testing them on variant MAGE-1.A1 peptides incorporating different amino acid substitutions. The epitopes recognized by the CTL proved to be different. While modifications of residues at positions 5, 6, or 7 in the antigenic peptide affected recognition by the three CTL, each of the modifications of residues at positions 1, 4, or 8 affected recognition by one CTL only. The sequences of both the alpha and beta chains of the T cell antigen receptor of the three CTL were completely different. The results indicate a long-lasting diversity in terms of fine specificity and of T cell antigen receptor structure in the repertoire of antitumor CTL derived from the blood of a melanoma patient and directed against a defined tumor antigen.
- Affiliations
Citations
Romero, P., Pannetier, C., Herman, J., Jongeneel, CV., Cerottini, JC., & Coulie, P. (1995). Multiple specificities in the repertoire of a melanoma patient’s cytolytic T-lymphocytes directed against tumor-antigen MAGE-1.A1. The Journal of Experimental Medicine, 182(4), 1019-1028. https://doi.org/10.1084/jem.182.4.1019 (Original work published 1995)